CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 141 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $792,582 | -40.7% | 67,800 | -31.8% | 0.01% | -38.5% |
| Q2 2023 | $1,335,681 | -18.9% | 99,381 | 0.0% | 0.01% | -18.8% |
| Q1 2023 | $1,647,737 | -10.9% | 99,381 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $1,848,487 | -35.6% | 99,381 | -55.6% | 0.02% | -27.3% |
| Q3 2022 | $2,872,000 | +70.9% | 223,812 | -6.7% | 0.02% | +83.3% |
| Q2 2022 | $1,681,000 | -24.3% | 239,795 | -10.5% | 0.01% | -7.7% |
| Q1 2022 | $2,222,000 | +83.6% | 268,012 | +50.0% | 0.01% | +85.7% |
| Q4 2021 | $1,210,000 | +27.8% | 178,700 | 0.0% | 0.01% | -12.5% |
| Q3 2021 | $947,000 | +38.7% | 178,700 | +50.4% | 0.01% | +33.3% |
| Q2 2021 | $683,000 | +187.0% | 118,800 | +48.5% | 0.01% | +100.0% |
| Q3 2020 | $238,000 | -35.7% | 80,000 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $370,000 | +26.3% | 80,000 | +45.2% | 0.00% | +33.3% |
| Q3 2019 | $293,000 | – | 55,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |